ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

pumitamig

Also written as “Pumitamig”, “PM8002” and “BNT327”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Small Cell Lung Carcinoma · Breast Neoplasms · Carcinoma, Hepatocellular · Colorectal Neoplasms, led by 4 companies.

Drug pagePumitamig: every studyAll 36 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since May 14, 202434 company-led studies, 32 open or runningCo-development: BioNTech and Bristol Myers Squibb, Jun 2025Next primary completion: Jan 1, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
BioNTechits history only2321 open or runningphase 3since May 14, 2024Feb 15, 2023Jan 1, 2027phase 2 · NCT05879055
Bristol-Myers Squibb99 open or runningphase 3since Oct 23, 2025Sep 26, 2024Mar 15, 2028phase 2 · NCT07871214
Boehringer Ingelheimits history only11 open or runningphase 2since Sep 22, 2026Sep 22, 2026Apr 17, 2030phase 2 · NCT07843940
DualityBioits history only11 open or runningphase 2since Apr 9, 2025Apr 9, 2025Jun 30, 2030phase 2 · NCT06953089
  • Named in Bristol-Myers Squibb’s own pipeline as pumitamig, phase 3, as of Oct 29, 2026 (source).

Also a collaborator on its studies: BioNTech (Shanghai) Pharmaceuticals, MediLink Therapeutics (Suzhou) and Genmab.

How these companies relate

From the companies’ own releases and filings, each linked; the registry does not say.

How Boehringer Ingelheim and DualityBio relate to it is not in the registry or these sources.

History and studies of Bristol-Myers Squibb only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Sep 26, 2024First study: phase 2 study in Lung NeoplasmsFirst studyNCT06618287 · 416 planned · United States, Australia, Canada and more
  2. Feb 13, 2025Named pumitamigINNProposed as its International Nonproprietary Name in WHO's List 132 · before, PM8002, BNT327
  3. Jun 2, 2025Bristol Myers Squibb develops it with BioNTechCo-developmentWorldwide, profits and losses shared equally · announced · BioNTech
  4. Oct 23, 20252 phase 3 studiesNCT07221357, NCT07221149
  5. Dec 17, 20252 phase 2 studiesNCT07293351, NCT07291076
  6. Jan 21, 20262 phase 3 studies in Carcinoma, Non-Small-Cell LungNCT07361510, NCT07361497
  7. Jun 26, 2026Phase 2 study in Carcinoma, Non-Small-Cell LungNCT07680764 · 160 planned · United States, Argentina, Australia and more
  8. Oct 7, 2026Phase 2 study in Carcinoma, Non-Small-Cell LungNCT07871214 · 80 planned · United States, Australia, Canada and more

Ahead

  1. Mar 15, 2028Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT07871214
  2. Sep 15, 2028Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT07680764
  3. Oct 15, 2029Primary completion: phase 2 study in Carcinoma, HepatocellularNCT07291076
  4. Nov 28, 2029Primary completion: phase 2 study in Carcinoma, Renal CellNCT07293351

TargetBeta

“A bispecific antibody targeting both the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274) and vascular endothelial growth factor A (VEGF-A), with potential immune checkpoint inhibitory, anti-angiogenic and antineoplastic activities. Upon adm…”NCIt, read by Claude
“A bispecific antibody targeting both the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274) and vascular endothelial growth factor A (VEGF-A), ”NCIt, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
HLX37Fosun Pharmaphase 32

Studies

All 9 Bristol-Myers Squibb leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07871214Carcinoma, Non-Small-Cell Lung · United States, Australia, Canada and more2Not yet recruitingMar 15, 202880
NCT07680764Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more2RecruitingSep 15, 2028160
NCT07361510Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more3RecruitingOct 14, 2031750
NCT07361497Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more3RecruitingSep 18, 2030850
NCT07293351Carcinoma, Renal Cell · United States, Argentina, Australia and more2RecruitingNov 28, 2029474
NCT07291076Carcinoma, Hepatocellular · United States, Australia, Chile and more2RecruitingOct 15, 2029198
NCT07221357Colorectal Neoplasms · United States, Argentina, Australia and more3RecruitingFeb 2, 2030990
NCT07221149Stomach Neoplasms · United States, Argentina, Australia and more3RecruitingNov 8, 2030690
NCT06618287Lung Neoplasms · United States, Australia, Canada and more2RecruitingFeb 26, 2031416

How it is read

Names in the registry

  • “Pumitamig”, 18 entries
  • “PM8002”, 11 entries
  • “BNT327”, 3 entries
  • “BNT327 Dose Level 1 (DL1)”, 2 entries
  • “BNT327 Dose Level 2 (DL2)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.